Alzprotect SAS
Therapeutic Solutions for Neurodegeneration
France
12 employees
Grant
Total: $16.34M
Biotechnology, Pharmaceutical
General Information
Get notified when Alzprotect SAS moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Alzprotect SAS
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biotechnology
About Alzprotect SAS
Taxonomy: biopharmaceutical company, drug development, neurodegenerative diseases, Alzheimer's disease, tauopathies, rare diseases, clinical trials, neuroscience research, pharmaceutical industry, biotech startups
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | •••••• | 1 |
|
01 Jun 2022 |
| Series B | •••••• | 1 |
|
22 Jan 2018 |
| Series A | •••••• | 2 |
|
11 Jun 2014 |
| Venture Round | •••••• | 1 |
|
01 Nov 2008 |
| Non Equity Assistance | •••••• | 1 | •••• •••• | 13 Feb 2007 |
Alzprotect SAS Alternatives & Competitors
Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.
We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic...
A leading CRO with unparalleled expertise in intricate cell biology, focusing on human neurodegenera...
FAQ About Alzprotect SAS
Don't just browse. Track.
Signal Tracker monitors Alzprotect SAS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
